An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Michigan Rogel Cancer Center

About this trial

This early phase I trial determines where and to what degree the tracer \[68Ga\] Ga-FAPI-04 accumulates in normal and cancer tissues in patients with high grade neuroendocrine cancer. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research \[68Ga\] Ga-FAPI-04. Because some cancers take up \[68Ga\] Ga-FAPI-04, it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.

Eligibility criteria

Qualifiers

Age ≥ 18 years old

Previous low uptake of [68Ga] Ga-DOTATATE PET/CT scan OR

Krenning Score ≥ 3 OR

Ki67 index ≥ 20%

Disqualifiers

Pregnancy or lactation

Patient recently underwent surgery with wound healing

Trial design

Treatments tested in this trial

  • Computed Tomography
  • Gallium Ga 68-DOTA-FAPI-04
  • Positron Emission Tomography

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Michigan Rogel Cancer Center

Lead sponsor

Neuroendocrine Research Foundation

Collaborator